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ABSTRACT 
In recent years, there has been a growing interest in various biochemical markers for 
detecting acute and chronic alcohol consumption. Biochemical markers for acute and 
chronic drinking play important roles in detecting alcohol use, abuse and dependence in 
hospital settings, work place settings, traffic medicine and in forensic toxicology 
examinations. The alcohol biomarkers can be distinguished into two main classes: 
“short-term markers” and “long-term markers”. Short-term markers are sensitive 
enough to detect a single intake of alcohol e.g. ethanol, 5-hydroxytryptophol (5HTOL), 
ethyl glucuronide (EtG) and ethyl sulfate (EtS). Long-term markers detect chronic 
heavy drinking, or indicate body organ or tissue damage caused by long-term exposure 
to alcohol e.g. carbohydrate-deficient transferrin (CDT), phosphatidylethanol (PEth), γ-
glutamyl transferase (GGT), aspartate and alanine aminotransferase (AST and ALT), 
and the mean corpuscular volume of erythrocytes (MCV).  
Following alcohol consumption less than 5% of the ethanol is excreted 
unchanged via the urine, sweat and breath, while more than 95% instead becomes 
metabolized mainly in the liver in a two-stage oxidation process. A minor part 
undergoes non-oxidative metabolism to produce the phase II products EtG and EtS. 
The interest in EtG and EtS as biochemical markers for acute alcohol intake has 
primarily focused on the observation that the washout rates for these direct ethanol 
metabolites are much slower than for the parent compound, thereby allowing a longer 
detection time. A positive finding of EtG and/or EtS in urine or plasma thus provides 
a strong indication that the person recently drank alcohol, even if drinking is denied, 
since levels of EtG and EtS remain elevated for some time after ethanol itself is no 
longer detectable.  
The purpose of this thesis was to evaluate the accuracy of urinary EtG and EtS 
measurement and the clinical application as biochemical markers for acute alcohol 
consumption. Urinary EtG and EtS were determined by liquid chromatography-mass 
spectrometry (LC-MS). 
The current studies demonstrated that EtG is a direct metabolite of ethanol and 
represents a minor elimination pathway (<0.03%) in the human body and confirmed 
that EtG remains detectable in the urine for many hours after the ethanol has been 
eliminated. Drinking large amount of fluid prior to voiding was found to lower the 
urinary concentration of EtG, but this practice did not influence the concentration of the 
EtG/creatinine ratio, no significant accumulation of EtG or 5HTOL was observed upon 
multiple-dose administration of ethanol, and the detection time in urine for EtG was 
demonstrated to be longer than for 5HTOL. It was found that EtG but not EtS is 
sensitive to bacterial hydrolysis. To reduce the risk for obtaining false low or false-
negative EtG results specimens should be stored refrigerated or frozen prior to analysis. 
Plasma EtG was found useful in the emergency department to detect recent drinking 
even when ethanol is negative to confirm alcohol abstinence. In 87% of the cases the 
information about recent drinking provided by self-report agreed with the EtG and EtS 
results in an outpatient treatment program for alcohol and drug dependence. EtG and 
EtS may also be objective outcome measures when evaluating new treatment strategies 
and pharmacotherapies. 
In conclusion, the present results demonstrated that urinary EtG and EtS are very 
sensitive and specific biochemical markers for acute alcohol intake.  
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1. INTRODUCTION 
 
Alcohol is one of the most widely used addictive substances in the world and has been 
a part of human culture since the beginning of recorded history (1). Almost all societies 
that consume alcohol show related health and social problems. In Sweden, about 90% 
of the adult population use alcohol more or less regularly and at least 500.000 people 
drink alcohol in harmful amounts. It has been estimated that 10–15% of all Swedish 
men and 3–5% of the women are at risk of having serious alcohol problems, and many 
die from sickness or injury caused by alcohol (2). The use and abuse of alcohol cost the 
Swedish society enormous amounts each year, not only related to increased health care 
costs but to other factors such as lost productivity (2-4).  
In a Swedish study carried out in a surgical emergency ward, about 15% of the patients 
screened positive for hazardous alcohol consumption (5, 6). It was also demonstrated 
that brief assessment with feedback regarding riskful alcohol consumption could be a 
useful way to reduce harmful drinking. An elevated, harmful level of alcohol 
consumption may lead to higher rates of sickness absence, and the associated hangover 
symptoms also increase the risk of causing and getting involved in accidents (7). A 
Swedish workplace study indicated that individuals with moderately elevated or 
harmful levels of alcohol consumption show an increase in sick-days (8). These results 
should encourage workplaces to use alcohol screening, for example during routine 
health examinations at the company health care service.  
Collecting information about a person’s drinking habits is usually a difficult task. 
Screening for alcohol abuse can be performed by interview, or by using different 
alcohol questionnaires such as the AUDIT (9), CAGE (10) and Mm-MAST (11). 
However, it is well known that people may not always report their alcohol intake 
correctly, but often deny drinking or under-report the true amount (12, 13). For this 
reason, harmful drinking and alcohol abuse are probably much under-diagnosed. 
Accordingly, there is a need to find more objective methods to identify persons with 
elevated and harmful drinking levels in the first place, and to confirm abstinence from 
alcohol or detect relapse during outpatient treatment of those diagnosed with having 
alcohol-related problems.  
The most obvious objective way to confirm alcohol consumption is to test for the 
presence of alcohol (ethanol) in breath or body fluids. A problem with alcohol testing 
is that the ethanol is rapidly cleared from the body, and this method therefore suffers 
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from low sensitivity. To try to overcome this problem, various laboratory tests, or 
biochemical markers, for alcohol use and abuse have been suggested over the years. 
However, because many of these biochemical markers are indirectly associated with 
alcohol consumption, they have sometimes shown a low specificity for alcohol and/or 
a low sensitivity for harmful drinking, causing problems when introduced into 
clinical practice. Accordingly, there is a need and continuous search for new and 
improved alcohol markers. 
 
 
2. ETHANOL METABOLISM 
 
Ethanol is a small, polar molecule with a low molecular weight and weak charge, 
which facilitates penetration through biological membranes. After alcohol ingestion, 
the ethanol is rapidly absorbed from the stomach (~20%) and intestines (~80%) (14). 
The absorption becomes delayed if there is food in the stomach (15). Ethanol then 
distributes in total body water, which averages about 75% of the body mass for men 
and 66% for women, but the blood ethanol concentration obtained after drinking 
alcohol also depends on factors such as body weight and body fat.  
Less than 5% of the ingested ethanol is excreted unchanged in urine, breath and sweat, 
while the major part (>95%) is eliminated mainly in the liver in a two-stage oxidation 
process at a rate of about 0.1 g/kg/h (15) (Figure 1). The oxidation of ethanol to form 
acetaldehyde takes place in the cytoplasm of the hepatocytes by the action of NAD+-
dependent alcohol dehydrogenase (ADH). Acetaldehyde is further oxidized to acetate 
by NAD+-dependent aldehyde dehydrogenase (ALDH) in the mitochondria. The 
acetate enters the circulation and eventually forms carbon dioxide and water by 
oxidation in the peripheral tissues. Furthermore, a small amount of the ethanol becomes 
oxidized to acetaldehyde via CYP2E1, belonging to the cytochrome P450 family, in the 
microsomal ethanol oxidizing system (MEOS) or by catalase, but these systems appear 
to be less important for the overall elimination of ethanol.  
Another very small part of the ethanol undergoes non-oxidative metabolism to produce 
end products such as fatty acid ethyl esters (FAEE) via FAEE synthase, 
phosphatidylethanol (PEth) via phospholipase D, ethyl glucuronide (EtG) via UDP-
glucuronosyltransferase (UGT) and ethyl sulfate (EtS) via sulfotransferase (SULT) 
(Figure 1). 
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Figure 1. The major oxidative pathway and minor non-oxidative pathways for ethanol 
elimination in the human body. 
 
 
3. ALCOHOL DEPENDENCE 
 
The AUDIT was development by the WHO as a simple screening test to identify 
persons with hazardous, harmful or dependence patterns of alcohol consumption (16). 
Hazardous drinking is a pattern of alcohol consumption that increases the risk of 
harmful consequences for the user and results in consequences to physical and mental 
health. Alcohol-dependent person show a behavior of strong desire to consume alcohol, 
impaired control over the use, persistent drinking despite harmful consequences, higher 
priority given to drinking than other activities and obligations, and an increased alcohol 
tolerance and physical withdrawal reaction when using alcohol (17). 
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The criteria of alcohol dependence has been defined in different classification systems 
such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) published 
by the American Psychiatric Association in 2004 (Table 1), or the International 
Classification of Diseases, 10th revision (ICD-10) published by the World Health 
Organisation in 1993. 
 
 
 
Table 1. Definition of alcohol abuse according to DSM-IV criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A maladaptive pattern of alcohol use, leading to clinically significant 
impairment or distress, as manifest by three (or more) of the following, 
occurring at any time in the same 12-month period. 
 
1. Tolerance, as defined by either of the following: 
a) A need for markedly increased amounts of alcohol to achieve 
intoxication or desired effect. 
b) Markedly diminished effect with continued use of the same 
amount of alcohol. 
 
2. Withdrawal, as manifested by either of the following: 
a) The characteristic withdrawal syndrome for alcohol. 
b) Alcohol (or a closely related substance) is taken to relieve or 
avoid withdrawal symptoms. 
 
3. Alcohol is often taken in larger amounts or over a longer period than 
was intended. 
 
4. There is a persistent desire or unsuccessful effort to cut down or 
control alcohol use. 
 
5. A great deal of time is spent in activities necessary to obtain alcohol, 
use alcohol, or recover from effects. 
 
6. Important social, occupational, or recreational activities are given up or 
reduced because of alcohol. 
 
7. Alcohol use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been 
caused or exacerbated by alcohol.
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4. PHARMACOLOGICAL MEDICATIONS 
 
Treatment of alcohol dependence usually combines with psychosocial interventions, 
such as motivational interviewing (18, 19), cognitive behavioral therapy (20), 12-step 
treatment from the Alcoholic Anonymous model and pharmacological medications. 
Disulfiram (Antabuse®) is a well known drug which has been used clinically since the 
late 1940s. The mechanism of action is by inhibiting the degradation of alcohol by 
inhibition of ALDH. This causes an accumulation of acetaldehyde, the first metabolite 
of ethanol oxidation (Figure 1). Increasing levels of acetaldehyde leads to unpleasant 
effects such as flushing, tachycardia, headache and nausea. 
Naltrexone (Revia®) is a non-selective opioid antagonist, which has shown to reduce 
the rate of relapse into heavy drinking as well the as craving for alcohol (21).  
Acamprosate (calcium acetyl homotaurinate; Campral®), a modulator of glutamate 
neurotransmission, has demonstrated some ability to reduce drinking and increase the 
time spent abstinent (22-24). 
 
5. BIOCHEMICAL ALCOHOL MARKERS 
 
The need for improved biochemical markers to be used for detection of sustained, 
heavy alcohol consumption but also of recent drinking has been widely recognized (25-
28). The interest in and knowledge of alcohol biomarkers has also grown rapidly in 
recent years and biochemical markers have been demonstrated to play important 
clinical roles in detecting persons with harmful drinking levels or alcohol abuse in 
hospital settings (29), workplace settings (30), traffic medicine (31), and forensic 
toxicology (32). The biochemical alcohol markers are often distinguished into the 
following main classes: 
 
1. Markers of acute alcohol consumption (short-term markers) are laboratory tests 
sensitive enough to detect a single intake of alcohol within the previous ~24–
48 h, and include tests such as ethanol, 5-hydroxytryptophol (5HTOL) (33, 34), 
EtG (35, 36) and EtS (37). 
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2. Markers of chronic, heavy alcohol consumption (long-term markers) are 
laboratory test that can detect sustained, harmful intake of alcohol, and include 
carbohydrate-deficient transferrin (CDT) (38), PEth (39, 40), and the mean 
corpuscular volume of erythrocytes (MCV) (41), but also tests to indicate the 
organ and tissue damage caused by long-term alcohol exposure, such as the 
liver enzymes γ-glutamyl transferase (GGT) (41) and aspartate and alanine 
aminotransferase (AST and ALT) (42). 
 
3. Trait markers of alcohol dependence are tests aimed to indicate if a person has 
a genetic predisposition of becoming dependent on ethanol. Platelet 
monoamine oxidase (43) and adenylyl cyclase (44) have, for example, been 
proposed as trait markers for alcohol dependence. 
 
 
5.1. Sensitivity and specificity 
 
Much research has focused on developing new and more accurate biochemical markers 
for alcohol use and abuse. Biochemical markers are usually evaluated in terms of 
diagnostic sensitivity and specificity. The sensitivity and specificity for any 
biochemical marker depends on the cutoff, or threshold limit, set to distinguish between 
a normal and an abnormal value. The ideal marker should be both 100% sensitive and 
specific, although this is hardly ever achieved. A common problem when evaluating 
alcohol markers is also the difficulty to obtain correct information about drinking 
levels. The sensitivity and specificity for biochemical markers are calculated as 
follows: 
 
¾ Sensitivity (%) = True positives / (True positives + False negatives) 
 
¾ Specificity (%) = True negatives / (True negatives + False positives) 
   7 
6. MARKERS OF ACUTE ALCOHOL CONSUMPTION 
 
6.1. Ethyl glucuronide (EtG) 
EtG is a minor non-oxidative direct metabolite of ethanol that is formed by reaction 
with uridine-5-diphospho-β-glucuronic acid (UDPGA) catalyzed by the endoplasmic 
reticulum UDP-glucuronosyltransferase (UGT) enzymes (45-47). The pathway of 
ethanol elimination via conjugation with UDPGA was first described in 1901. In 1952, 
a dose-dependent formation of EtG, isolated as the tri-acetyl methyl ester, was 
demonstrated in rabbits, and 0.5–1.6% of the administered ethanol dose was excreted in 
the urine as EtG (48). EtG was later determined also in human urine (49-51). In 1995, 
EtG was synthesized and identified in human serum (50). The molecular weight of EtG 
is 222 g/mol and of penta-deuterated EtG (EtG-d5) used as internal standard 227 g/mol 
(Figure 2). 
The renewed interest in EtG is primarily related to its use as a biochemical marker for 
acute alcohol intake. This interest originates from the observation that the washout 
rate for EtG is much slower than for ethanol (35, 36), but also from the development 
of sensitive and specific analytical methods based on gas chromatographic-mass 
spectrometric (GC–MS) (36) and liquid chromatographic-mass spectrometric (LC–
MS) techniques (52). A positive finding of EtG in urine or serum thus provides a 
strong indication that the person was recently drinking alcohol, even in cases when 
the ethanol itself is no longer measurable. EtG was demonstrated to be eliminated 
with a half-life of ~2.5 h (35) and to show high inter-individual variation with a poor 
correlation with the concentration of ethanol (53). The latter observation can at least 
partly be explained by the time-lag between the excretion profiles for ethanol and 
EtG.  
The high sensitivity of EtG for recent drinking is evident from the observation that 
even intake of a very low dose (~7 g) of ethanol is detectable in the urine after 6 h 
(52). Depending on the amount of ethanol consumed, EtG has been reported to be 
measurable in the urine for up to 4 days after the last intake (54) (Figure 3). Except 
for urine and blood, EtG can also be detected in samples of hair (55-58), oral fluid 
(59), and in tissue extracts (60, 61).  
 
 
 
 
 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The molecular structures of EtG, EtG-d5, EtS and EtS-d5. 
 
 
 
6.2. Ethyl sulfate (EtS) 
EtS is another conjugated, direct ethanol metabolite that is formed by reaction with 
sulfate by the action of cytosolic sulfotransferase (62-65). In humans, the elimination 
pathway for ethanol via sulfate conjugation to produce EtS was first established in 2004 
by LC-MS (66). The molecular weight of EtS is 126 g/mol and of penta-deuterated EtS 
(EtS-d5) 131 g/mol (Figure 2). The human study also demonstrated that only a very 
small fraction (<0.1%) of the ingested ethanol undergoes sulfate conjugation. 
Furthermore, EtS showed very similar urinary excretion profiles as EtG, but EtS was 
typically present in lower amounts compared with EtG. Depending on the amount of 
ethanol consumed, EtS has been reported to be measurable in the urine for up to 4 days 
after the last intake (54) (Figure 3). Recently there has been an increased focus on EtS 
as a biochemical marker for acute alcohol intake (37, 67-70). 
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6.3. Fatty acid ethyl esters (FAEE) 
FAEE are products of non-oxidative metabolism of ethanol via FAEE synthase (71). 
FAEE have been proposed as a sensitive and specific biochemical marker of acute 
alcohol intake (72, 73). FAEE can be detected for up to at least 24 h after alcohol intake 
(74), although a recent study reported a faster elimination of FAEE compared with 
earlier studies (75) (Figure 3). FAEE may also be important in the pathogenesis of 
organ damage caused by alcohol abuse, since high FAEE concentrations are found in 
alcohol-related organ damage (76). 
 
 
6.4. 5-Hydroxytryptophol (5HTOL) 
During ethanol metabolism, there is an interaction with the metabolism of serotonin (5-
hydroxytryptamine; 5HT) resulting in a shift from production of 5-hydroxyindole-3-
acetic acid (5HIAA) towards formation of 5HTOL (77) (Figure 3). 5HTOL is normally 
the minor metabolite of 5HT (<1%) but its formation increases dramatically in a dose-
dependent manner after alcohol consumption. At the same time, the formation of the 
major metabolite 5HIAA becomes decreased (78). This metabolic shift from the 
oxidative towards the reductive 5HT pathway occurs because of competitive inhibition 
of mitochondrial ALDH by acetaldehyde and the increased cytosolic NADH/NAD+ 
ratio, both favouring 5HTOL formation at the expense of 5HIAA (79, 80). 
Furthermore, the reoxidation of 5HTOL to 5HIAL by ADH is inhibited during ethanol 
oxidation (81).  
Soon after drinking alcohol, the urinary 5HTOL concentration becomes markedly 
increased and will not return to baseline levels until several hours after the ethanol is no 
longer measurable (78) (Figure 3). Based on this time-lag, urinary 5HTOL has been 
used clinically as a sensitive biochemical marker of recent alcohol consumption (33, 
82). To secure the specificity of the marker, 5HTOL should be expressed as a ratio to 
5HIAA rather than to creatinine, because dietary serotonin (high amounts in banana 
and pineapple) might otherwise cause false-positive results. This practice also 
compensates for variations in the urinary concentration of 5HTOL caused by external 
and internal dilution of the urine (83). Gender or genetic variations in the ADH and 
ALDH isoenzyme patterns seemingly do not influence the baseline ratio of 
5HTOL/5HIAA (34, 84). The only known factor apart from alcohol intake that 
increases the urinary 5HTOL/5HIAA ratio is treatment with ALDH inhibitors such as 
disulfiram (Antabuse) and cyanamide (Dipsan®) (85). Testing of urinary 
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5HTOL/5HIAA as a biochemical marker for acute alcohol intake has been applied in 
clinical practice to confirm abstinence and detect relapse drinking during treatment of 
alcohol-dependent subjects in outpatient settings (86, 87). Furthermore, the 
5HTOL/5HIAA test has found uses in forensic medicine, because it can distinguish 
ingested from microbially formed ethanol, that might occur in postmortem specimens 
and in urine samples collected from diabetic patients with urinary tract infections (UTI) 
(83, 88). 
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Figure 3. The interaction between serotonin (5HT) and ethanol metabolism. 
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7. MARKERS OF CHRONIC ALCOHOL CONSUMPTION 
 
7.1. Carbohydrate-deficient transferrin (CDT) 
Transferrin is a glycoprotein that is synthesized by the liver with the specific function 
to transport iron (Fe3+) in the body (89). There is a glycoform microheterogeneity of 
human transferrin, usually resulting in non-detectable levels of asiolo- and monosialio-, 
<2% disialo-, 4.5–9% trisialo-, 64–80% tetrasialo-, 12–18% pentasialo-, and 1–3% 
hexasialotransferrin in serum (90-92). The International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) has identified disialotransferrin as the 
main target analyte for the alcohol marker CDT (93). After prolonged heavy alcohol 
consumption the glycoform pattern changes towards a higher concentration of disialo- 
and asialotransferrin (38, 94-98). The rather alcohol-specific increase of CDT makes it 
useful as a marker for chronic alcohol consumption (99, 100). To increase CDT, a 
relative large daily alcohol consumption is required, corresponding to ~50–80 gram 
ethanol per day for ~2 weeks or longer (38, 101-103) (Figure 4). CDT has a half-life of 
1.5–2 weeks (38, 95, 99, 104). Methods to analyze CDT are for example a candidate 
reference HPLC method (105) and commercial assays based on immunochemistry, 
capillary zone electrophoresis or HPLC.  
 
7.2. Phosphatidylethanol (PEth) 
PEth is a group of abnormal phospholipids which are formed only in the presence of 
ethanol via the action of phospholipase D (39, 40, 106). Normally phospholipase D 
uses water as substrate to produce phosphatidic acid. PEth has a half-life of ~4 days and 
is detectable in alcohol abusers up to 2–4 weeks after alcohol withdrawal (107, 108) 
(Figure 4). The PEth concentration in blood correlates with the amount of ethanol 
intake in alcohol abusers (108, 109) and it is thus a promising new biomarker of 
chronic alcohol use (110-112). The current methods used for PEth analysis include 
HPLC (108, 113) and LC-MS (40, 114). 
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7.3. Gamma-glutamyltransferase (GGT) 
The enzyme GGT is a non-specific index of liver damage and is also used as a 
biomarker for chronic alcohol consumption (96, 115, 116). The half-life of GGT is 2–3 
weeks and the level usually returns to normal within 4-5 weeks after drinking is 
discontinued (96, 117-119) (Figure 4). The drinking intensity and frequency and even 
regular intake of low alcohol levels (1–40 g/day) may affect GGT (115, 120). There are 
many other causes for an elevated GGT such as drugs, diabetes, smoking, age, gender 
and non-alcoholic liver disease (121-124). 
 
7.4. Aspartate and alanine aminotransferase (AST and ALT) 
The enzymes AST and ALT are non-specific indicators of liver and tissue damage that 
are also used as biomarkers for chronic alcohol consumption (25, 125-128) (Figure 4). 
The half-life of AST and ALT is 2–3 weeks (118). The sensitivity and specificity of 
AST and ALT for alcohol are fairly low (118, 129). Calculation of the AST/ALT ratio 
may help to differentiate between alcoholic and non-alcoholic liver damage, with an 
enzyme ratio over 2.0 suggestive of alcohol aetiology (115, 123, 128). There are also 
many other causes for an elevated AST such as muscle disorders, myocardial 
infarction, skeletal muscle trauma and non-alcoholic liver disease (42, 118). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Estimated detection times for alcohol intake by different markers. 
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8. AIMS  
 
8.1. General aim 
The purpose of this work was to evaluate the accuracy of urinary EtG and EtS as 
biochemical markers for acute alcohol intake in clinical practice, by identifying 
possible sources of error that can interfere with the result of the analysis and cause 
false-negative or false-positive EtG and EtS results. 
 
8.2. Specific aims 
 
¾ To compare the urinary excretion characteristics of EtG with that of ethanol in 
healthy human subjects, with focus on the effect of water-induced diuresis. 
 
¾ To investigate the stability, reproducibility and any possible accumulation of 
EtG and 5HTOL in urine, after healthy human subjects ingested single and 
multiple oral doses of ethanol. 
 
¾ To evaluate whether the presence of Escherichia coli, or any other common 
human pathogen in urine may cause hydrolysis of EtG and/or EtS by bacterial 
β-glucuronidase and sulfatase enzymes, hence resulting in false-negative 
results, and by that to investigate the impact of urine sample handling. 
 
¾ To determine the value of plasma EtG as a marker to obtain information about 
alcohol consumption in an emergency department. 
 
¾ To determine the information about recent alcohol consumption obtained by 
urinary EtG and EtS when introduced as a routine test in an outpatient treatment 
program for alcohol and drug dependence. 
 
¾ To examine the value of urinary EtG and EtS testing compared with self-reports 
for detection of prior drinking in alcohol-dependent outpatients. 
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9. MATERIALS AND METHODS 
 
9.1. Experimental design 
 
Study I  
Six healthy volunteers (three women and three men), all being social drinkers, 
abstained from alcohol consumption for at least 48 h before starting the experiment 
according to self-report. A light morning meal was allowed approximately 1.5 h before 
the subjects ingested an ethanol dose of 0.5 g/kg as beer (5%, v/v) in 30 min. At 3 h 
from the start of ethanol intake, they drank an equal volume of tap water. Urine 
sampling was performed immediately before starting the experiment and at timed 
intervals over 31.5 h. The samples were stored at -20°C until taken for analysis of 
ethanol using an enzymatic ADH method and of EtG by LC-MS (52).  
 
Study II 
Nine healthy female, all social drinkers were told to avoid alcohol beverages for one 
week before entering the study and during the study period only the alcohol from the 
study was allowed. The subjects drank ethanol in juice (8%, w/v) or placebo (juice) in 
random order. The intervention consisted of 0.4 g/kg ethanol or placebo twice daily 
(morning and evening) over 8 consecutive days, starting in the evening of day 1. Urine 
sampling was performed every morning (first morning void) during the 8-days drinking 
period and for the 3 following days (days 9–11). The samples were stored at -20°C 
until analyzed of ethanol by GC, EtG by LC-MS, 5HTOL by GC-MS and 5HIAA by 
HPLC. 
 
Study III 
Fresh clinical urine specimens (n = 46) with confirmed bacterial growth were selected 
to include different common human pathogens. The samples were supplemented with 1 
mg/L each of EtG and EtS and were then split into test tubes without preservatives that 
were placed at -20°, 4° and 22°C. Urine samples without the addition of EtG and EtS 
served as controls. At the start and after 1, 2 and 5 days of storage at 4° and 22°C, 
samples were placed at -20°C until taken for analysis of EtG and EtS by LC-MS. In a 
separate experiment, fresh clinical urine specimens (n = 8) confirmed to be positive for 
E. coli were supplemented with 1 mg/L each of EtG and EtS and incubated in test tubes 
containing sodium fluoride (10 mg NaF/mL urine) as preservative or without any 
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additive. At the start and after 5 days of storage at 22°C, samples were placed at -20°C 
until taken for analysis of EtG and EtS by LC-MS. 
 
Study IV 
Male patients (n = 81) aged 18–76 years admitted to the emergency department (ED) 
and diagnosed to be minimally injured and clinically non-intoxicated participated in 
this study. A detailed description of the experimental design is found elsewhere (130). 
The patients were asked to complete a computerized alcohol questionnaire including 
the 10 questions of the standardized AUDIT questionnaire (16, 131) and a self-report 
(paper and pencil) questionnaire (130) about alcohol consumption data. The questions 
included the type and amount of alcoholic beverage consumed on weekdays and during 
weekends, and the time, type and amount of last intake. To adjust for the variable doses 
of alcohol and different times between drinking and blood sampling the estimated time 
since completed ethanol elimination was calculated for each patient by using an 
elimination rate of 0.15 g/kg/h and a distribution volume of 0.7 × body weight. Blood 
was collected and stored at -20°C until analyzed for EtG by LC–MS. 
 
Study V 
A total of 24 patients (21 men and 3 women, aged 21–52 years) with alcohol and/or 
drug dependency undergoing outpatient treatment agreed to participate in this study. In 
connection with regular return visit to the clinic patients were invited to leave a urine 
sample and complete a single-question form about recent drinking (“Did you drink any 
alcohol in the past 3 days – Yes/No?”). The urine sample and the single-question form 
were de-identified and only connected by a code with no possibly to track the patient. 
The subjects were allocated to 3 sub-groups depending on the type of outpatient 
treatment program: Group A included 8 individuals (7 men and 1 woman) undergoing 
treatment for alcohol dependence; Group D included 10 individuals (9 men and 1 
woman) being treated for drug dependence (former heroin addicts); and Group M 
included 6 individuals (5 men and 1 woman) undergoing methadone maintenance 
therapy for opioid addiction. The samples were placed at -20°C until taken for analysis 
of EtG and EtS by LC–MS. 
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Study VI 
This study involved 56 treatment-seeking individuals (30 men and 26 women, mean age 
50 years) recruited via advertisements in a local newspaper. The inclusion criteria 
were a male or a non-pregnant/non-nursing female age 18–65 years fulfilling criteria 
for alcohol dependence according to DSM-IV and with a goal of controlled drinking, 
willingness to give informed consent, complying with the procedures, and having 
consumed alcohol on at least 15 of the past 90 days according to self-report. 
Exclusion criteria were seeking complete abstinence, a psychiatric disorder diagnosis 
according to DSM-IV (including all forms of substance dependence other than nicotine 
and alcohol), current use of psychoactive medications to manage schizophrenia, a bipolar 
disorder or major depression, inpatient alcohol detoxification within the last 4 days, 
acamprosate medication during the last 12 months, and use of illegal drugs during the 
course of the study. The patients were randomized to 21 days of either oral 
acamprosate (2 g/day) or placebo treatment in a double-blind design, as described in 
detail elsewhere (132). Return visits to the ward for blood and urine sampling and filling 
out alcohol questionnaires were made on day 7, 14 (leaving urine was optional on these 
days) and 22 (a urine sample was mandatory). On day 22, they were also required to 
provide a negative breath alcohol test. The questionnaire focused on prior alcohol 
consumption, expressed as the number of standard drinks (1 drink = 12 g ethanol) per 
day over the past 3 days, using a time-line follow-back method. The patients were 
instructed to refrain from alcohol during the treatment period, evidence of drinking was 
not grounds for study discontinuation unless warranted for clinical safety. The samples 
were placed at -20°C until taken for analysis of EtG and EtS by LC-MS. 
 
 
9.2. Ethical approval 
 
Study I–III and V was approved by the ethics committee at the Karolinska Institutet 
(Dnr KI 99-338). Study IV obtained ethical approval from the International Review 
Board of the University Hospital Charité, Berlin, Germany (EK-Vorg: 1514/2001). 
Study VI was approved by the ethics committee at the Karolinska Institutet (Dnr KI 
2007/995-31). 
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9.3. Analytical methods  
 
Ethanol 
In Study I, ethanol was determined enzymatically using yeast ADH (133) on a Hitachi 
917 analyzer (La Roche Ltd, Basel, Switzerland). The limit of quantification (LOQ) of 
this method was 0.5 mmol/L. In Study II, ethanol was determined by a headspace GC 
method with an LOQ of 0.1 mmol/L (134). 
 
EtG and EtS in urine 
Urinary EtG and EtS were determined by a negative ion electrospray LC–MS method 
(52, 66). The LC–MS system used for Study I and II was a Perkin-Elmer 200 LC and a 
Sciex API 2000 MS, and in Study III–VI an Agilent 1100 series LC-MS. All urine 
samples, controls and standards were stored at -20°C until use. Before analysis, the 
samples were mixed and centrifuged and a 10-µL aliquot of urine, control or standard 
was mixed (1:10) with 90 µL of the internal standard solution (deuterium-labelled EtG 
and EtS; EtG-d5 and EtS-d5) and transferred to autosampler vials. Of the mixture, 10 
µL were injected directly into the LC-MS system, which was equipped with a 5-µm 
Hypercarb analytic column (100 × 2.1 mm i.d.). The mobile phase consisted of 25 
mmol/L formic acid containing 5% acetonitrile and the flow rate was 0.2 mL/min. 
Analysis was performed in the negative ion mode, with selected ion monitoring (SIM) 
of m/z 221 for EtG, m/z 226 for EtG-d5, m/z 125 for EtS and m/z 130 for EtS-d5. The 
concentrations of EtG and EtS were calculated from the peak-area ratios to the internal 
standards, by reference to calibration curves. The LOQ of the method was 0.10 mg/L 
for EtG and EtS, the intra- and interassay coefficients of variation (CV) were less than 
12%, and the range of linearity was 0.1–1500 mg/L (52, 66). 
 
EtG in plasma 
Measurement of EtG in plasma was performed by a negative ion electrospray LC-MS 
method (52, 66). The LC-MS system used for Study IV was an Agilent 1100 series LC-
MS. All plasma samples, controls and standards were stored at -20°C until use. Before 
analysis, a 200-µL aliquot of plasma was mixed with 1.0 mL methanol containing 
internal standard and centrifuged at 14.000 g for 10 min. The supernatant was 
evaporated to dryness under a stream of nitrogen and the final content dissolved in 100 
µL of de-ionized water. A 10-µL aliquot was injected directly into the LC–MS system, 
which was equipped with a 5-µm Hypercarb analytic column (100 × 2.1 mm i.d.). The 
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mobile phase consisted of 25 mmol/L formic acid containing 5% acetonitrile and the 
flow rate was 0.2 mL/min. Analysis was performed in the negative ion mode, with SIM 
of m/z 221 for EtG, m/z 226. A calibration curve for EtG prepared by serial dilution 
with EtG negative plasma samples was linear (r2 = 0.994, p <0.0001) in concentration 
range 0.1–100 mg/L. The EtG concentration of unknown samples was determined from 
the peak-area ratios between EtG and EtG-D5 by reference to the calibration curve. The 
LOQ was ~0.15 mg/L EtG.  
 
5HTOL 
Urinary 5HTOL was determined by GC–MS using an HP 5972 (Hewlett Packard, Palo 
Alto, CA) (84). 5HTOL is mainly excreted in conjugated form with glucuronic acid 
(135, 136). Before analysis, the urine samples were spiked with an internal standard 
(deuterium-labelled 5HTOL; 5HTOL-d4) and incubated at 37°C for 1 h with β-
glucuronidase (β-D Glucuronoside glucuronosohydrolase, EC 3.2.1.31 from E. coli), 
resulting in complete hydrolysis of the 5HTOL glucuronide. The free 5HTOL was then 
extracted with diethyl ether and finally derivatized. Separation was achieved on a 
DB1701 capillary GC column (30 m × 0.25 mm i.d.; J&W Scientific, Folsom, CA). 
GC-MS analysis was performed with SIM of m/z 451 for 5HTOL and m/z 454 for 
5HTOL-d4. The concentration of 5HTOL was calculated from the peak-area ratios to 
the internal standard by reference to a calibration curve. The LOQ of the method was 
~25 nmol/L. 
 
5HIAA 
Urinary 5HIAA was determined by high-performance liquid chromatography (HPLC) 
with electrochemical detection (137). Before analysis, the urine samples were spiked 
with an internal standard (5-hydroxyindole-2-carboxylic acid). Separation of 5HIAA 
was achieved on a Nucleosil-120 C18 analytic column (50 × 4.0 mm i.d.). The mobile 
phase consisted of 105 mmol/L citric acid, 12 mL/L methanol, 50 µmol/L EDTA and 
25 µmol/L sodium octylsulfate (pH 2.2) and the flow rate was 1 mL/min. The 
concentration of 5HIAA was calculated from the peak-area ratios to the internal 
standard by reference to a calibration curve. The LOQ of the method was ~1 µmol/L. 
 
 
 
 
   19 
Creatinine 
Analysis of creatinine is performed in clinical practice to evaluate kidney function, but 
also as a way to monitor and compensate for the degree of urine dilution (138). In Study 
I, creatinine was determined by the routine Jaffé reaction, where creatinine reacts with 
picric acid under alkaline conditions to form a red-coloured product that is measured on 
a Hitachi 917 analyzer. The LOQ of the method was 0.5 mmol/L. In Study II, creatinine 
was determined by the VITROS CREA Slides which is a multilayered analytical 
element coated on a polyester support were the final reaction produces a coloured 
product that was measured on a VITROS 250 Chemistry System (Ortho Clinical 
Diagnostics, Rochester, NY). The LOQ of the method was 0.08 mmol/L. 
 
Pathogens in human urine specimens 
Human urine specimens with confirmed growth of different common human pathogens 
at densities of 103 to >105 colony-forming units (CFU)/mL, as identified and quantified 
by culture on standard solid media, were obtained from the Department of Clinical 
Microbiology at the Karolinska University Hospital, Solna, Sweden. 
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10. RESULTS AND DISCUSSION 
 
10.1. Study I 
According to self-report, all participants taking part in this study had abstained from 
alcohol for at least 48 h. This was confirmed by the observation that all urine samples 
collected immediately before starting drinking ethanol were negative for ethanol and 
EtG. Intake of ethanol at 0.5 g/kg (594–986 mL beer; 25.0–41.5 g) resulted in a marked 
increase in urine volume and a concomitant drop in the urinary creatinine 
concentration. The ethanol concentration increased rapidly and reached a peak value of 
17.0 ± 2.5 mmol/L (mean ± SD) at 1.5 h after start of the experiment (Figure 5A). The 
EtG concentration also started to increase and was detectable already in the first urine 
collection after ethanol intake at 1 h (Figure 5B). At 3 h after starting drinking ethanol, 
the same volume of tap water was ingested and this produced another increase in urine 
volume and a drop in the creatinine concentration. The ethanol excretion curve was not 
influenced by the water intake (Figure 5A), whereas this caused a marked decrease in 
the rising EtG concentration curve from 44.6 ± 22.6 mg/L at 3 h to 13.8 ± 7.9 mg/L 1 h 
later (Figure 5B). The EtG concentration increased again after 5.5 h. At 6 h after 
ethanol intake, ethanol was no longer measurable in urine and the EtG concentration 
started to fall with a half-life of ~2.5 h.  
When EtG was expressed relative to the creatinine concentration, this ratio was not 
markedly influenced by the water intake (Figure 5C). The urinary EtG/creatinine ratio 
reached a peak value of 8.8 ± 3.5 mg/mmol in the 4-h collection, and thereafter the ratio 
value decreased with a half-life of ~2.5 h, which is in good agreement with previous 
and later observations (35, 139, 140). There were considerable variations in the 
EtG/creatinine excretion profiles between different individuals.  
After the intake of 0.5 g/kg ethanol, ethanol was detectable in urine for 6 h whereas 
EtG was detectable for 22.5–31.5 h, albeit in the end usually at levels below 1 mg/L. It 
was calculated that less than 0.03% (range 0.013–0.025%) of the 0.5 g/kg ethanol dose 
consumed was recovered in the urine as EtG. This has also been confirmed in later 
studies (59, 69, 70). 
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Figure 5. Time-course of diuresis and the urinary concentrations of ethanol (A) and 
EtG (B), and the urinary EtG/creatinine ratio (C), after six healthy volunteers drank 
594–986 mL export beer (corresponding to 0.5 g/kg ethanol) in 30 min and 3 h later 
the same volume of water. 
 
 
The interest in EtG as a biochemical marker of acute alcohol intake relates to it being a 
direct metabolite of ethanol detectable for several hours to some days longer than 
ethanol, implying both a high specificity and sensitivity for recent alcohol consumption 
(35-37, 68, 141-143). The high sensitivity of EtG was confirmed by the original 
observation that intake of a very small ethanol dose (~7 g) resulted in detectable EtG 
levels over at least 6 h (52, 144). Furthermore, following heavy drinking, EtG has been 
reported to be detectable for up to 4 days after the last ethanol intake (54, 143). EtG can 
also be detected in samples of hair, body fluids and tissues (55-60, 145, 146).  
The results of the present study showed that, compared with ethanol, EtG was 
detectable in the urine for an extra ~15–25 h, albeit in the end mostly at low 
concentrations (<1 mg/L). Of the administered ethanol dose (0.5 g/kg), only about 
0.02% was recovered in urine as EtG. This is considerably lower than the 0.5–1.6% 
previously reported from studies on rabbits (48) but our results have later been 
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confirmed in other studies (59, 69). Whether the relative formation of EtG in humans is 
dose-dependent remains to be elucidated.  
The present study also pointed at one important limitation of this new alcohol marker. 
It was demonstrated that ingestion of a water load prior to urine sampling lead to a 
dramatic reduction in the EtG concentration, whereas, in agreement with previous and 
later observations (37, 53, 147), this did not influence the concentration of ethanol. 
Accordingly, it is possible to decrease the urinary concentration of EtG to fall below the 
LOQ of the analytic method, simply by drinking moderate to large amounts of water or 
any other fluid prior to voiding. Internal and external dilution of the urine are well-
known strategies among drug abusers, to try to avoid detection when being tested for 
illicit drug use (148).  
This study also demonstrated that the interference by water-induced diuresis on the EtG 
concentration could be overcome, by expressing EtG as a ratio to creatinine. 
Normalization of values to creatinine is common practice to compensate for unusually 
dilute or concentrated urine samples (138, 147, 149). However, even when EtG was 
expressed as a ratio to creatinine, there were considerable inter-individual variations in 
the excretions profiles, which were later confirmed by others (59, 69, 150). The 
individual variation could depend on factors such as differences in ethanol distribution 
and elimination, enzyme activities, enzyme induction, kidney disease, and 
polymorphism of the UGT enzymes (45, 47, 151).  
In summary, the results of the present study confirmed that EtG remains detectable in 
the urine for several hours after the ethanol itself has been eliminated. The results also 
showed that it is possible to markedly lower the urinary concentration of EtG simply by 
drinking large amount of water or fluid prior to voiding, whereas this did not influence 
the concentration of ethanol or the EtG/creatinine ratio. Checking the urine for an 
abnormally low creatinine concentration or expressing urinary EtG as a ratio to 
creatinine, therefore may be recommended in routine clinical use, to detect and 
compensate for urine dilution. It was also demonstrated that conjugation of ethanol 
with glucuronic acid to form EtG represents a very minor elimination pathway for 
ethanol in humans. 
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10.2. Study II 
In this study, healthy female subjects drank ethanol (8%, w/v) in juice at 0.4 g/kg or 
placebo (juice) twice daily (morning and evening) in random order for 8 consecutive 
days. Thereafter, they were followed for another 3 days (days 9–11) without ethanol 
intake. Spot urine samples were collected according to the study protocol. During the 
placebo drinking period on days 1–8 and also on days 9–11, all urine samples were 
found to be negative for ethanol and showed 5HTOL/5HIAA ratios below the reference 
value (<15 nmol/µmol). All urine samples except two (two subjects showed one 
positive EtG value each; 0.60 and 0.12 mg/L) were also negative for EtG.  
During the ethanol drinking period on days 3–8, ~56% of the urine samples were found 
to be positive for ethanol, ~78% showed an increased 5HTOL/5HIAA ratio, and all 
(100%) were positive for EtG. However, the individual values during the ethanol 
drinking period were highly variable between subjects (Figure 6). Accordingly, the 
urinary ethanol values ranged between 0–7.3 mmol/L, the 5HTOL/5HIAA ratio 
between 2–109 nmol/µmol, the EtG/creatinine ratio between 0.1–4.5 mg/mmol, and the 
EtG concentration between 1.4–71 mg/L. For some individuals, there was also a 
considerable variation in the results on different days. The urine samples collected on 
day 9, which was ~14–15 h after the last intake of 0.4 g/kg ethanol, were negative for 
ethanol and showed a normal 5HTOL/5HIAA ratio, while EtG and the EtG/creatinine 
ratio were positive. One subject was found positive for EtG (0.26 mg/L) also in the 
morning on day 10, which was ~38 h after the last intake. This subject showed the 
highest EtG value (80.5 mg/L) at 4 h after the last intake on day 8.  
Compared with the starting values, the ethanol elimination rate was significantly 
increased by 24% on average at the end of drinking period (day 8) (134). However, 
there were no significantly differences between the ratios of EtG/creatinine and 
5HTOL/5HIAA at 4 h after ethanol intake on days 1 and 8, whereas the EtG/creatinine 
ratio at 15 h was significantly lower on day 8. 
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Figure 6. Urinary concentrations of ethanol and EtG, and the ratios of EtG/creatinine 
and 5HTOL/5HIAA, in first morning urine void samples collected during ethanol (0.4 
g/kg twice daily, once in the morning and once in the evening) and placebo drinking 
periods. 
 
An increased urinary ratio of 5HTOL/5HIAA has been used clinically for several years 
as a sensitive biochemical marker for recent alcohol consumption (33, 69, 70, 82, 86, 
87, 141). More recent studies have demonstrated that analysis of EtG in urine can also 
be useful for this purpose (28, 35, 36, 152-154). The present results confirmed previous 
observations that EtG and the urinary 5HTOL/5HIAA ratio both become increased 
shortly after consumption of alcohol and they remained increased for many hours 
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longer than ethanol itself. In this respect, the detection time for EtG was found to be 
longer than for 5HTOL/5HIAA. It is possible that the longer detection time for EtG 
compared with 5HTOL/5HIAA simply results from the higher concentration of EtG, 
because the EtG level is more than 100-fold higher than the 5HTOL level after ethanol 
intake (35, 78). As for the urinary 5HTOL/5HIAA ratio, EtG can be expressed as a 
ratio to creatinine, to compensate for variations in the concentration caused by urine 
dilution (83, 155). 
During the placebo period, two subjects showed positive results for urinary EtG, albeit 
at low levels. It cannot be excluded that these resulted from unintentional intake, as 
ethanol is also present in so-called “alcohol-free” beverages (<0.5% ethanol). The 
endogenous ethanol concentration has been estimated not to be high enough to produce 
a detectable concentration of EtG (52, 156). 
In cases of prolonged heavy drinking, EtG has been reported to be detectable for up to 
5 days after the last alcohol intake (54, 141, 143). This observation, together with other 
reports, suggested that EtG may accumulate in the body upon prolonged drinking (35, 
54). However, the present study found no indication of EtG accumulation, nor a 
gradually increased 5HTOL/5HIAA ratio, upon repeated ethanol exposure of 0.8 g/kg 
ethanol per day for a period of ~1 week. After 8 days of drinking, the elimination rate 
of ethanol was found to be increased by 24% (134). This observation could possibly 
explain the significantly lower EtG/creatinine ratio observed at 15 h after the last intake 
compared with on day 1. Accordingly, the lower EtG/creatinine ratio was most likely 
related to the lower concentration of ethanol.  
During the alcohol drinking period, there were considerable variations in ethanol, EtG, 
and 5HTOL/5HIAA levels in the morning urine samples, both between and within 
subjects. This was probably due to a combination of effects such as occasional voiding 
during night-time, and some hours difference in the time between drinking the ethanol 
and collecting the urine sample, as well as biological variations. The variability for EtG 
could not be explained simply by urine dilution, as it was evident also when EtG was 
normalized to creatinine.  
In summary, the results of this study confirmed that the urinary excretion of EtG and 
5HTOL become increased following acute ethanol intake, and also remains detectable 
for many hours after the ethanol is no longer measurable. There was no significant 
accumulation in the body of either EtG or 5HTOL, upon multiple-dose administration 
of ethanol at 0.8 g/kg per day for ~1 week. This study therefore supports the use of 
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urinary EtG and an elevated 5HTOL/5HIAA ratio as sensitive and specific tests to 
assess recent drinking in light to moderate as well as chronic alcohol consumers. When 
used for this purpose, the detection time for EtG was found to be longer than for 
5HTOL/5HIAA. This has later been confirmed in other studies (69, 141). 
 
10.3. Study III 
In the majority (68%) of the urine specimens with confirmed growth of E. coli, the EtG 
concentration was found to decrease over time on storage at 22°C but not at 4° or -20°C 
(examples are given in Figure 7). In 3 specimens, a complete hydrolysis of the EtG 
added (1 mg/L) was noted after 24 h at 22°C. In 2 specimens that contained very high 
EtG concentrations (37.3 and 39.3 mg/L) already before EtG supplementation, the 
levels decreased to 11.2 and 0.7 mg/L, respectively, after storage for 5 days at 22°C. 
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Figure 7. Effect of storage time and temperature on the hydrolysis of EtG by bacterial 
β-glucuronidase in clinical urine specimens containing E. coli. 
 
 
In 1 of 3 urine specimens containing Klebsiella pneumoniae and the single specimen 
containing Enterobacter cloacae, the EtG concentration also decreased over time after 
storage at 22°C. None of the uropathogens tested (Table 2) caused hydrolysis of EtS 
after samples were supplemented with 1 mg/L EtS and stored at 22°C for 1–5 days. 
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Table 2. Uropathogens tested for causing falsely low or false-negative EtG or EtS 
results due to hydrolysis by bacterial β-glucuronidase and sulfatase. 
 
Uropathogen identified Urine specimens
tested 
n 
Specimens causing 
hydrolysis of EtGa 
n (%) 
Specimens causing 
hydrolysis of EtSa 
n  
 
Escherichia coli  
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17 (68) 
 
0 
Enterococcus species 5 0 (0) 0 
Group B streptococci 3 0 (0) 0 
Klebsiella pneumoniae 3 1 (33) 0 
Proteus mirabilis 2 0 (0) 0 
Pseudomonas aeruginosa 2 0 (0) 0 
Staphylococcus saprophyticus 2 0 (0) 0 
Citrobacter freundii 1 0 (0) 0 
Enterobacter cloacae 1 1 (100) 0 
Enterobacter aerogenes 1 0 (0) 0 
Morganella morganii 1 0 (0) 0 
 
a EtG and EtS (1 mg/L each) were added to fresh UTI specimens, which were then stored in sealed plastic 
vials (without preservative) at 22°C for 1–5 days, after which EtG and EtS were measured by LC-MS. 
 
 
To evaluate the effect of chemical preservatives, 8 urine specimens confirmed positive 
for E. coli were supplemented with 1 mg/L each of EtG and EtS and the volume was 
then split into two test tubes, one containing preservative (10 mg NaF/mL urine) and 
the other without any additive. The samples were then stored at 22°C for 5 days. In 6 
specimens, hydrolysis of EtG was observed in the tubes without preservatives after 
storage at 22°C for 5 days, whereas EtG was found to be completely stable on storage 
in the tubes containing NaF. No decrease in the EtS concentration on storage was 
observed for any of these samples. 
After consumption of alcohol beverages, a very small fraction (<0.1%) of the ingested 
ethanol undergoes conjugation reactions to produce EtG and EtS (66, 155). EtG and 
more recently EtS have thus been introduced as sensitive and specific biochemical 
markers of recent alcohol intake and appears to follow the same pattern of urinary 
excretion as EtG but exposure in lower concentration (37, 54, 67-70, 145, 153, 157). 
However, glucuronide and sulfate conjugates are hydrolyzed by β-glucuronidase and 
sulfatase enzymes. β-Glucuronidase is present with high activity in most strains of E. 
coli, which is the most common bacterium isolated in clinical laboratories and also the 
predominant pathogen (~80%) in urinary tract infections (158). Sulfatase activity has 
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also been detected in many bacteria (159) but not in E. coli (160, 161) or only in very 
low amounts (162).  
The present study demonstrated that bacterial β-glucuronidase, especially if samples 
are positive for E. coli, can hydrolyze EtG and cause false low or false-negative results. 
These results agree with previous studies showing that most E. coli strains possess β-
glucuronidase activity (163-165) (Klebsiella pneumoniae and Enterobacter cloacae 
also caused a gradual disappearance of EtG, but the rate of EtG hydrolysis was 
typically slower that for E. coli under the same conditions. These observations are 
consistent with previous results, which indicate that other pathogens also possess low 
β-glucuronidase activity (164, 165). Our results therefore concluded that EtG might not 
be stable on storage, if urine specimens taken for analysis are infected with pathogens 
possessing β-glucuronidase activity. In contrast to EtG, EtS was indicated to be 
completely stable to bacterial hydrolysis. The disappearance of EtG was found to be 
temperature dependent, with refrigeration or freezing of samples, or use of test tubes 
containing NaF as preservative, being effective to prevent hydrolysis.  
In summary, the present study demonstrated that EtG but not EtS is sensitive to 
bacterial hydrolysis, particularly in specimens infected by E. coli. To prevent bacterial 
growth and hydrolysis of EtG, the urine specimens should be refrigerated or frozen. 
Using test tubes containing NaF is also recommended. Since EtS shows a similar time 
course as EtG after alcohol consumption, it may be recommended, and an analytical 
advantage, to measure EtS instead of EtG, or to combine EtG with EtS which is 
possible by LC–MS (37, 66). 
 
10.4. Study IV 
This study compared the value of plasma EtG testing with the information about 
alcohol consumption obtained using the standard alcohol biomarkers GGT and CDT 
and the AUDIT questionnaire in an emergency department. Male patients (n = 81) 
diagnosed to be minimally injured and clinically non-intoxicated were screened about 
their alcohol consumption (amount and time of alcohol intake) by using the 
computerized AUDIT questionnaire and a paper-and-pencil assessment. Blood samples 
were collected for determination of ethanol, EtG (LC–MS) and GGT in plasma and 
%CDT in serum (%CDT immunoassay). Based on the AUDIT questionnaire 28% were 
classified at a risk for alcohol related problem (>8 points) and 63% as social drinkers 
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(1-7 points) and 9% as non-drinkers (0 points). Only 4% (3) of the patients showed a 
detectable ethanol concentration (0.01–0.07 g/L) but 38% (31) showed a detectable EtG 
in plasma (0.16–39.5 mg/L). In 9% (7) of the patients EtG was detectable in blood >24 
h after calculated time for complete elimination, assuming an elimination rate of 0.15 
g/kg/h and a distribution volume of 0.7 × body weight and in 5% (4) patients EtG was 
detectable for >48 h afterwards, which indicated misreporting (Figure 8). A later study 
suggested that the suspected misreporting data could instead have been related to renal 
failure (151). 
 
 
Figure 8. The time course of plasma EtG versus time to (negative values) or since 
(positive values) calculated completed ethanol elimination from the body, assuming an 
ethanol elimination rate of 0.15 g/kg/h. 
 
EtG did not correlate with the long-term biomarkers %CDT or GGT, or the AUDIT 
results, but with the time since estimated completed ethanol elimination. Patient that 
appeared intoxicated at admission to the ED were excluded in this study. The findings 
that 4 of 7 patients that reported recent alcohol intake had no detectable ethanol which 
limited the value of ethanol testing in this setting. The high frequency (38%) of the 
patients being positive for EtG in plasma, confirmed that they had consumed alcohol 
within the past ~12–24 h (50, 140). A high alcohol intake is a common cause of trauma 
and patient with chronic and heavy alcohol consumption exhibit a higher incidence of 
morbidity and mortality following surgery (166), therefore it is important allow 
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intervention and reduction of alcohol-related harm (29, 129, 167, 168). This study 
employed plasma samples for testing EtG although EtG is detectable for considerable 
longer time in urine (50, 59, 140). In a later controlled study results showed that urinary 
EtG (Cmax) were 160 times higher than blood (59). However it might not always be 
feasible to collect urine in the ED and most of the patients participating in this study 
were reluctant to leave urine sample whereas blood sampling was more tolerated. Even 
if blood is taken the detection time in plasma EtG is still longer that for ethanol but not 
as long as urinary EtG (59). EtG testing in blood was found useful in the ED as a way 
to detect recent drinking, even in cases of a negative ethanol test, and to confirm 
abstinence from alcohol. This plasma EtG is a sensitive and specific short-term 
biomarker provides valuable additional information about individual drinking habits 
and might also be helpful to identify an alcohol hangover. 
 
10.5. Study V 
This study was voluntary, anonymous and included urine sampling and a single-
question form about recent drinking (“Did you drink any alcohol in the past 3 days – 
Yes/No?”). 24 patients (21 men and 3 women, aged 21–52 years) agreed to take part in 
this evaluation about recent drinking. The subjects were allocated to 3 sub-groups 
depending on the type of outpatient treatment program: Group A included 8 individuals 
(7 men and 1 woman) undergoing treatment mainly for alcohol dependence; Group D 
included 10 individuals (9 men and 1 woman) being treated for drug dependence 
(former heroin addicts); and Group M included 6 individuals (5 men and 1 woman) 
undergoing methadone maintenance therapy for opioid addiction. Each of the 24 
patients provided 4–14 (mean 8.9, median 9) urine samples over a 2–8-week (mean 5.4, 
median 5) period, the total number of samples being 214 (Table 3). In 211 (98.6%) of 
the 214 cases, the anonymous self-report form about recent alcohol use was 
successfully completed. Altogether 26% of the urine samples from 12 of 24 patients 
tested positive for EtG (0.5–434 mg/L, mean = 47.1, median = 13.6) and/or EtS (range 
= 0.1–87 mg/L, mean = 10.8, median = 2.6). One patient (D4) (Table 3) was only 
positive for EtS (2.4–12.0 mg/L, mean = 5.8, median = 3.3) and these EtS results were 
confirmed by LC–MS/MS analysis (66). In 21 of the 211 self-reports collected from 11 
patients, ingestion of alcoholic beverages was admitted in the 3-day period prior to 
urine sampling. In 87% of the 211 complete cases (both self-report and urinary data 
were available), the information provided by self-report agreed with the corresponding 
EtG and EtS results (true positives or true negatives) (Table 3). 
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Table 3. Frequency of recent alcohol consumption according to anonymous self-
reports and urinary EtG and EtS measurement in outpatient treatment programs for 
alcohol and drug dependence. 
 
 
a Outpatients undergoing treatment programs for primarily (A) alcohol dependence or (D) drug 
dependence, or (M) opiate addicts participating in methadone maintenance therapy. 
b “Any intake of alcoholic beverages in the past 3 days – Yes/No?”. 
c The reporting limits were > 0.5 mg/L for EtG and > 0.1 mg/L for EtS. 
d These urine samples were only positive for EtS. 
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Table 1. Frequency of recent alcohol consumption according to anonymous self-reports and 
urinary EtG and EtS measurement in outpatient treatment programs for alcohol and drug 
dependence. 
 
Self-reported drinkingb / Urinary EtG and EtS resultsc Group 
and ID 
no.a 
Sex 
(M/F) 
Data 
collection 
(weeks) 
Samples
(N) Pos/Pos Neg/Neg Pos/Neg Neg/Pos Missing/Pos Missing/Neg 
A1 F 5 12 1 11     
A2 M 5 9  9     
A3 M 5 10  7 1 2   
A4 M 6 10  10     
A5 M 5 7  7     
A6 M 5 8  8     
A7 M 3 4    4   
A8 M 2 4  4     
          
D1 M 7 10  10     
D2 M 7 12 10 2     
D3 F 6 9 3 4 2    
D4 M 8 9    8d 1d  
D5 M 6 10 9 1     
D6 M 6 9  6 1 2   
D7 M 8 14 1 11 2    
D8 M 4 11  11     
D9 M 8 12 4 7  1   
D10 M 5 7 3 4     
          
M1 M 5 10  8    2 
M2 F 5 7  7     
M3 M 5 7  7     
M4 M 4 7  7     
M5 M 5 8 5  2 1   
M6 M 5 8   7 1       
Total: 21M/3F 130 214 36 148 9 18 1 2 
 
a Outpatients undergoing treatment programs for primarily (A) alcohol dependence or (D) drug dependence, or 
(M) opiate addicts participating in methadone m intenance therapy. 
b “Any intake of alcoholic beverages in the past 3 days – Yes/No?”. 
c The reporting limits were > 0.5 mg/L for EtG and > 0.1 mg/L for EtS. 
d These urine samples were only positive for EtS.
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In 9% of the cases EtG and EtS tested positive while this was not admitted by self-
report and in another 4% of the cases recent drinking was reported but EtG and EtS 
were negative. There were significantly more positive self-reports of recent drinking 
when sampling occurred on Mondays (32.6%) compared with on Fridays (14.3%; p = 
0.0068, Chi-square test). There was also a higher frequency of positive EtG and EtS 
findings in urine specimens collected on Mondays (32.2%) compared with on Fridays 
(21.5%) but this difference was not statistically significant (p = 0.146). The frequency 
of drinking (Figure 9) was significantly higher in the drug dependence group compared 
with the alcohol dependence group, both according to self-reports (34.3% vs. 3.1% of 
cases; p <0.0001) and urinary EtG and EtS results (40.8% vs. 10.9%; p = 0.0001).  
 
 
 
 
 
 
 
 
 
 
Figure 9. Indications of recent drinking based on anonymous self-report (any drinking 
in the past 3 days?) or a positive urinary EtG and EtS test in an outpatient treatment 
program for alcohol and drug dependence. “Overall agreement” is the total frequency 
of concordant results (the sum of results being positive for alcohol by both measures or 
negative by both measures). The reporting limit was 0.5 mg/L for EtG and 0.1 mg/L for 
EtS. 
 
 The frequency of drinking was also significantly higher in the drug dependence group 
compared with the methadone maintenance therapy group, according to urinary EtG 
and EtS (12.8%; p = 0.0013) but not to self-reports (17.8%; p = 0.0672). Furthermore, 
there was a significant difference in the frequency of self-reported drinking between the 
alcohol dependence and methadone maintenance therapy groups (p = 0.0225) but not 
according to urinary EtG and EtS (p = 0.993). Only 2 out of 10 (20%) patients in the 
drug dependence group abstained completely from drinking according to both 
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measures, compared with 5 of 8 (63%) in the alcohol dependence group and 3 of 6 
(50%) in the methadone maintenance therapy group. 
Alcohol represents a common problem among patients dependent on illicit drugs and 
heavy drinking is associated with an increased risk for relapse into drug use and 
discharge from treatment (169, 170), therefore monitoring of alcohol can be 
recommended for early detection. When new biomarkers are introduced in routine 
clinical use, the specificity for alcohol and the potential consequences for the patient of 
a false-positive or false-negative result need to be considered (171). A positive 
laboratory result taken as proof of relapse into alcohol and/or drug abuse might lead to 
discharge from treatment.  
Several studies have provided data on the urinary detection times for EtG and EtS 
following intake of different alcohol doses, which represents important information in 
clinical practice (143). It should be considered that even consumption of a very small 
ethanol dose (<10 g), and use of ethanol-based products such as mouthwash (144) and 
hand sanitizers (172) may result in a detectable EtG level in urine (37, 52, 70). 
Furthermore, incorrect storage of infected samples implies a risk for false-positive as 
well as false-negative EtG results (150, 155, 173, 174), although this is seemingly a 
minor problem with EtS. Related to this, the cut-off used to distinguish between a 
positive and a negative result is always a critical issue. However, the risk for such 
problems was indicated to be low for the reporting limits applied for EtG (>0.5 mg/L) 
for EtS (>0.1 mg/L) in the present study (143). In this study the outcome was very high, 
with 99% of all self-report forms being completed successfully and even the 
corresponding EtG and EtS results agreed well (range for overall agreement = 83.5–
89.1%). One major reason can be that the participation was voluntarily and did not 
influence their treatment in any way. If the self-reports had not been anonymous, these 
results would probably have been considerably lower (12, 13). The frequency of 
drinking was markedly lower among patients undergoing treatment for alcohol 
dependence compared with the other two groups. These results suggest that the patients 
in the treatment program focusing primarily on alcohol-related problems were more 
motivated to avoid drinking. Although this study based on a small sample size, these 
results suggest that urinary EtG and EtS testing is a valuable objective tool for detection 
of recent drinking during outpatient treatment. Biomonitoring of alcohol use may be 
important in any treatment program for alcohol and/or drug dependence. 
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10.6. Study VI 
This study involved 56 patients (26 women and 30 men) diagnosed for alcohol 
dependence according to DSM-IV. The patients were recruited via advertisements in 
a local newspaper and instructed to participate in a double-blind study with either 
tablets of acamprosate (2 g/day) or placebo. They were told to abstain from drinking 
during the 3 week treatment period, beginning on the day they took their first dose. 
During the treatment period, patients made weekly return visits to the ward to fill out 
questionnaires about alcohol intake (TLFB) and to leave a urine sample on day 7, 14 
and 22 (leaving urine sample at day 7 and 14 was optional). On day 22, they were also 
required perform a negative breath alcohol test. On the initial day of the study (day 0), a 
urine sample was obtained from 46 (82%) patients. Because leaving urine was optional 
on day 7 and 14, much fewer urine samples were collected on those days (52% and 
61%, respectively), and these results were therefore excluded from the calculations. On 
the final study day (day 22), 47 (87%) patients delivered the mandatory urine sample. 
From 19 patients on acamprosate medication and 21 on placebo, a urine sample was 
obtained both on day 0 and 22. 
On the first study day, 33 of the 46 patients (72%; 65% for acamprosate and 78% for 
placebo) tested positive for recent drinking according to EtG (LOQ >0.5 mg/L) and EtS 
(LOQ >0.1 mg/L). On the final day, the frequency of positive urine tests was 
significantly reduced to 30% among those randomized to acamprosate medication (p = 
0.0374) and 33% for the placebo group (p = 0.0050) (Figure 10).  
 
 
Figure 10. Frequency of urine samples positive for EtG and EtS in alcohol-dependent 
patients randomly allocated to 21 days of acamprosate medication (2 g/day) or 
placebo. Samples were collected on the initial (day 0) and final (day 22) day of the 
study. 
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However there were no significant differences between the treatment groups. When the 
results for both groups were combined, the urinary EtG and EtS concentrations on day 
22 were significantly lower compared with on day 0 (Figure 11). For comparison all 
patients tested negative for ethanol in breath on the final day. 
 
 
 
 
 
Figure 11. Box-and-whisker plot showing the distribution of urinary EtG and EtS 
concentrations on day 0 and 22 in samples collected from patients allocated to 
acamprosate medication or placebo. The Box-and-whisker plot shows the median, 25th 
and 75th percentiles, minimum and maximum values, and outside (○) and far out (●) 
values. 
 
 
Altogether 63 urine samples from 41 patients (21 on acamprosate and 20 on placebo) of 
the totally 156 (40.4%) specimens collected within this study tested positive for EtG 
(range 0.50–300 mg/L, mean 44.6, median 15.2) and EtS (range 0.11–61.0 mg/L, mean 
10.2, median 3.78). When separated by treatment group, there were 30 of 80 (36.5%) 
EtG and EtS positive samples in the patients on acamprosate and 33 of 76 (43.4%) 
positives in the placebo group.  
In addition to the 63 EtG and EtS positive urine samples, another 13 (8.3%) contained 
measurable amounts (LOD for EtG <0.1 mg/L and EtS <0.05 mg/L) of both 
metabolites but at levels below the routine LOQ. Accordingly, based on urinary EtG 
and EtS testing, almost half (48.7%) of all specimens indicated recent drinking.  
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Based on self-report, in 26 of the 63 positive cases (41.3%) alcohol consumption was 
admitted (range 1–8 standard drinks, mean 4.3, i.e. ~50 g ethanol) on the previous day; 
in 19 of these drinking was also admitted 2 and/or 3 days back. In another 33 cases, 
alcohol consumption was only admitted 2 and/or 3 days back. Two patients denied any 
drinking over the past 3 days. Self-report data was missing for 2 subjects. In 28 cases 
where the patients reported alcohol consumption (range 1–8 drinks, mean 4.1 ~50 g 
ethanol) on the day before urine sampling, 26 (92.9%) urine samples tested positive for 
EtG and EtS. In the remaining cases where no drinking on the previous day was 
admitted, 35 (27.6%) samples were positive for EtG and EtS. 
In the 93 urine samples that tested negative for EtG and EtS (<LOQ), there were no 
positive self-reports of drinking on the day prior to sampling, while in 15 cases alcohol 
consumption was admitted 2 and/or 3 days back.  
Altogether there were 77 cases of self-reported drinking over the 3-days period prior to 
each sampling, ranging from 1–25 standard drinks (12–300 g ethanol, mean 7.3 drinks 
~90 g ethanol). Overall the self-reported quantity of drinking over the past 3 days prior 
to urine sampling showed good correlation with the EtG and EtS concentrations (Figure 
12). 
 
 
Figure 12. Correlation between self-reported drinking, expressed as number of 
standard drinks (12 g ethanol) over the past 3 days, and the corresponding urinary (A) 
EtG and (B) EtS concentrations. 
 
This study population comprised treatment-seeking patients participating in a 3-weeks 
randomized double-blind study to determine the effect of acamprosate medication on 
alcohol-cue reactivity and alcohol priming (132). Although the patients were instructed 
to refrain from alcohol during the treatment period, and the goal of abstinence was 
further supported by councelling in connection with the return visits to the ward, the 
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results revealed that almost 50% of all urine samples tested positive for EtG and EtS. 
The EtG and EtS concentrations showed good correlation with the self-reported 
quantity of drinking over the past 3 days prior to urine sampling. However, it must be 
highlighted that evidence of drinking was not a ground for study discontinuation, 
except for a positive breath test on day 22. This could be a reason behind continued 
drinking during the treatment period and for the good reliability of the self-reports. This 
observation, together with that of other studies, suggests that there is a good correlation 
between self-report and the EtG and EtS results in cases where alcohol intake during 
treatment does not lead to any consequence (175). Other studies have shown that, when 
admitting alcohol use could have negative consequences to the individual, then the self-
report information may be unreliable (13, 84). 
In agreement with previous studies, the present results indicated a dose- and time-
dependent sensitivity of urinary EtG and EtS as biomarkers for detection of recent 
drinking. It has been demonstrated that both metabolites can pick up ingestion of even 
very small amounts of alcohol for roughly 1 day afterwards, and larger doses for 2 or 
possibly 3 days (52, 59, 68, 69, 143, 176). 
In cases when drinking was admitted in the day before sampling, 93% of the urines 
tested positive for EtG and EtS. In addition, the EtG and EtS biomarker also detected a 
large number (28%) of positive cases when prior drinking had been denied. Overall, 
however, the results indicated that both the frequency and amount of drinking were 
significantly reduced at the end of the treatment period compared with the starting 
values. In this respect, acamprosate apparently offered no advantage over placebo. This 
is in line with earlier trials demonstrating an effect of acamprosate medication over 
placebo typically after a longer treatment period.  
Taken together, the present results highlight the value of using sensitive and specific 
alcohol biomarkers to detect alcohol consumption during outpatient treatment of 
patients with alcohol-related problems, and as objective outcome measures when 
evaluating new treatment strategies and pharmacotherapies, and not to rely solely on 
patient self-reports. 
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11. CONCLUSIONS 
 
The present results demonstrated that conjugation of ethanol to produce EtG represents 
a very minor elimination pathway (<0.03%) for ethanol in humans. The results further 
confirmed previous observations that EtG remains detectable in the urine for many 
hours after ethanol itself has been eliminated from the body and is no longer 
measurable. The detection time for urinary EtG was found to be longer than for the 
5HTOL/5HIAA ratio following alcohol intake. There was no significant accumulation 
of either EtG or 5HTOL upon multiple-dose administration of ethanol, indicating that 
both markers are useful to detect recent drinking in light as well as heavy alcohol 
consumers. By drinking large volumes of water or fluid prior to voiding, it is possible 
to lower the urinary concentration of EtG, whereas this did not influence the 
concentration of ethanol or the EtG/creatinine ratio. To compensate for urine dilution, it 
is therefore recommended to express urinary EtG as a ratio to creatinine or to check 
samples for an abnormally low creatinine content. The present results further 
demonstrated that EtG but not EtS is sensitive to bacterial hydrolysis, particularly in 
specimens infected by E. coli. To prevent bacterial growth and hydrolysis of EtG, the 
specimens should be stored refrigerated or frozen, or samples should be collected in test 
tubes containing NaF as preservative. EtG testing in plasma was found to be useful in 
the ED as a way to detect recent drinking, even in cases of a negative ethanol test and to 
confirm abstinence from alcohol. The plasma EtG result also provide valuable 
additional information about individual drinking habits and might be helpful to identify 
an alcohol hangover. The EtG and EtS testing might be a helpful tool for detecting 
recent drinking in any treatment program for alcohol and/or drug dependence. EtG and 
EtS may also be objective outcome measures when evaluating new treatment strategies 
and pharmacotherapies. In clinical practice, it may be recommended to combine EtG 
and EtS testing which is possible by LC–MS. Accordingly, as previously shown for 
5HTOL/5HIAA, urinary EtG and EtS can be used as sensitive and specific biochemical 
markers for acute alcohol intake. This sensitive and specific alcohol biomarker may be 
valuable for objective detection of recent alcohol consumption and relapse drinking, a 
helpful tool in interventions that may reduce a hazardous/harmful alcohol use, in 
hospital settings, and as an objective outcome measures when evaluating new treatment 
strategies and pharmacotherapies. 
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